28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: SB656933
DRUG: SB656933
DRUG: Placebo

Sponsor

GlaxoSmithKline